What is Probiusdx?
Probiusdx is at the forefront of integrating biology and artificial intelligence (AI) to advance human health. The company leverages its proprietary Quantum Electrochemical Spectroscopy (QES) technology, which facilitates a paradigm shift from reagent-dependent to data-centric biological analysis. This innovative platform allows for the precise detection and quantification of biological specimens with minimal sample input and without the need for additional reagents. Probiusdx primarily serves innovators and researchers within the biosciences sector, fostering collaborations to expedite biomedical research and support applications in areas such as biomarker discovery, pre-clinical modeling, and quality control. Their services are engineered to deliver robust AI-driven analysis through decentralized collection of multidimensional biological datasets, effectively addressing critical data gaps in the life sciences.
How much funding has Probiusdx raised?
Probiusdx has raised a total of $2.4M across 1 funding round:
Debt
$2.4M
Debt (2025): $2.4M, investors not publicly disclosed
What's next for Probiusdx?
With the recent major strategic investment, Probiusdx is poised to accelerate its development and market penetration. The enterprise-level funding context suggests a focus on scaling operations, expanding its technological capabilities, and potentially forging new strategic partnerships. The company's unique approach to biological data analysis, combining QES technology with AI, positions it for significant growth in the rapidly evolving health-tech landscape. Future endeavors will likely concentrate on translating its research into tangible applications, further solidifying its role as a key player in the intersection of biology, AI, and healthcare innovation.
See full Probiusdx company page
